1Odvina CV,Zerwekh JE,Rao DS. Severely suppressed bone turnover:a potential complication of alendronate therapy[J].Journal of Clinical Endocrinology and Metabolism,2005.1294-1301. 被引量：1
2Jamal SA,Dion N,Ste-Marie LG. Atypical femoral fractures and bone turnover[J].New England Journal of Medicine,2011.1261-1262.doi:10.1177/1352458511408479. 被引量：1
3Bjorgul K,Reigstad A. Atypical fracture of the ulna associated with alendronate use[J].ACTA ORTHOPAEDICA,2011.761-763.doi:10.1016/S1470-2045(10)70009-7. 被引量：1
4Puah KL,Tan MH. Bisphosphonate-associated atypical fracture of the femur:Spontaneous healing with drug holiday and re-appearance after resumed drug therapy with bilateral simultaneous displaced fractures--a case report[J].ACTA ORTHOPAEDICA,2011.380-382.doi:10.3109/17453674.2011.581267. 被引量：1
5Schilcher J,Michaelsson K,Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft[J].New England Journal of Medicine,2011.1728-1737.doi:10.1056/NEJMoa1010650. 被引量：1
6Abrahamsen B,Eiken P,Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate:a register-based national cohort study[J].Journal of Bone and Mineral Research,2009,(6):1095-1102.doi:10.1359/jbmr.081247. 被引量：1
7Rizzoli R,Akesson K,Bouxsein M. Subtrochanteric fractures after long-term treatment with bisphosphonates:a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis,and International Osteoporosis Foundation Working Group Report[J].Osteoporosis International,2011.373-390. 被引量：1
